NCT04731623View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

August 12, 2021

Study Completion Date

September 11, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

ION904

ION904 will be administered by SC injection.

DRUG

Placebo

Placebo (0.9% sterile saline) will be administered by SC injection.

Trial Locations (1)

M9L 3A2

BioPharma Services, Inc., Toronto

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY